Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis

NCT ID: NCT05419427

Last Updated: 2023-10-13

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 552 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-11-11
• Study Completion Date: 2024-11-24

Brief Summary

Denosumab of Intas is biosimilar denosumab candidate under development by Intas Pharmaceutical Limited (Biopharma Division). Denosumab of Intas is already approved by Indian drug licensing authority- Drug Controller General (India) for marketing in Indian population since 2018.As per regulatory requirement, a comparative clinical study to establish Pharmacokinetic, Pharmacodynamic and Immunogenicity equivalence is required to conclude therapeutic equivalence to obtain marketing authorization of a biosimilar investigational product. This is a multicenter, randomized, double-blind, active controlled study in approximately 552postmenopausal women with osteoporosis.

An extension of the study is planned after completion of the initial 1 year of treatment. This extension is with the objective of submitting data on safety, and Immunogenicity, after switching of Prolia treatment arm to either Prolia or Intas denosumab for 6 months. This switching data is applicable only for FDA submission. Only patients who have undergone PK assessment will be eligible for the extension phase.

Conditions

Osteoporosis, Postmenopausal

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Denosumab Solution for injection in single use prefilled syringe 60 mg permL

Unit Dose Strength 60 mg per mL,Dosage Level 60 mg once every 6 months, Route of Administration-Subcutaneous injection

Group Type: EXPERIMENTAL

Denosumab

Intervention Type: DRUG

Denosumab 60 MG/ML

Prolia® Solution for injection in single use prefilled syringe 60 mg per mL

Unit Dose Strength 60 mg per mL,Dosage Level 60 mg once every 6 months,Route of Administration-Subcutaneous injection

Group Type: ACTIVE_COMPARATOR

Denosumab-Ref

Intervention Type: DRUG

Denosumab 60 MG/ML

Interventions

Denosumab

Denosumab 60 MG/ML

Intervention Type: DRUG

Denosumab-Ref

Denosumab 60 MG/ML

Intervention Type: DRUG

Other Intervention Names

INTP23; Prolia

Eligibility Criteria

Inclusion Criteria

• Participant must sign an ICF to participate in the study indicating that she understands the purpose of, and procedures required for the study as described in this protocol and is willing to and will be able to adhere to requirement of the protocol.
• Participant must be 55 to 90 years of age (both inclusive), at the time of signing the informed consent.
• Participants whose absolute bone mineral density T-score is less than equal to -2.5 and greater than equal -4.0 at the lumbar spine as measured by DXA (dual-energy x-ray absorptiometry), confirmed by the independent central imaging team
• At least two vertebrae in the L1-L4 region and at least one hip joint are evaluable by DXA, confirmed by the independent central imaging team.
• Postmenopausal ambulatory female and not considered to be of child-bearing potential if:

a. Women are considered post-menopausal and not of child-bearing potential if, i. They have had 12 months of natural (spontaneous) amenorrhea (no vaginal bleeding or spotting) with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) OR ii. Six months of spontaneous amenorrhea with serum FSH levels greater than 40 mIU per mL OR iii. Have had surgical bilateral oophorectomy (with or without hysterectomy) at least six months ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment if she is considered not of child-bearing potential

Exclusion Criteria

• Documented medical history of clinically significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
• Documented medical history of known allergies, hypersensitivity, or intolerance to denosumab or its excipients (refer to the IB)
• Documented medical history of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of the results, such as Pagets disease, osteomalacia, osteogenesis imperfecta, osteopetrosis, rheumatoid arthritis, ankylosing spondylitis or any other joint disease limiting mobility, Cushings disease, hyperprolactinemia, malabsorption syndrome
• Contraindications to the use of denosumab or Vitamin D and Calcium as per IB/local prescribing information at screening and/or baseline
• Documented medical history and/or current evidence of any of the following oral/dental conditions

1. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw.

2. Active dental or jaw condition which requires oral surgery.

3. Planned invasive dental procedure expected during study period.

4. Current evidence non-healed dental or oral surgery.

5. Current evidence of poor oral hygiene

6. Ill-fitting denture

• Current hyper- or hypocalcemia, defined as albumin-adjusted serum calcium outside the normal range at screening.
• Current, uncontrolled hyper- or hypoparathyroidism and history of hypoparathyroidism, per participant report or chart review. PTH outside the normal range (15-65 pg/mL) as assessed by central laboratory
• Current, uncontrolled hyper- or hypothyroidism, defined as thyroid stimulating hormone outside of the normal range (TSH-0.465 to 4.68 mIU/L) at screening.
• 25 (OH) Vitamin D lower than 20 ng/mL as assessed by the central laboratory at Screening. Vitamin D repletion will be permitted, and participants may be rescreened once.
• History and /or presence of 1 severe fracture or 2 moderate vertebral fractures
• Smokers or who have smoked within last 06 months prior to start of the study.
• Administration of bisphosphonate as follows: - c. IV Bisphosphonate in the past 3 years d. Oral bisphosphonates treatment for osteoporosis i. More than 3 years of cumulative use ii. Any dose received within 6 months prior to randomization iii. More than 1 month of cumulative use between 6 and 12 months prior to randomization
• Teriparatide or any PTH analogs treatment received within 12 months prior to randomization.
• Systemic oral or transdermal estrogen, SERMs, or calcitonin treatment of more than 1 month of cumulative use within 6 months prior to randomization.
• Androgen deprivation or hormonal ablation therapy of more than 1 month of cumulative use within 6 months prior to randomization.
• Tibolone or cinacalcet treatment received within 3 months prior to randomization
• Systemic glucocorticoids: Greater than equal to 5 mg prednisone equivalent per day for more than 10 days within 3 months prior to randomization.

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Intas Pharmaceutical Limited (Biopharma Division)

UNKNOWN

Sponsor Role: collaborator

Lambda Therapeutic Research Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

S. R. Kalla Memorial Gastro & General Hospital

Jaipur, Rajasthan, India

Site Status: RECRUITING

Countries

India

Central Contacts

Mr Prashant Modi

Role: CONTACT

prashantmodi@lambda-cro.com

917940202375

Provided Documents

Document Type: Study Protocol

View Document

Other Identifiers

CTRI/2021/09/036190

Identifier Type: REGISTRY

Identifier Source: secondary_id

0774-19

Identifier Type: -

Identifier Source: org_study_id